ClinicalTrials.gg
CompletedNCT05128058Updated Nov 13, 2023Results posted

A Target Occupancy Study With Ritlecitinib.

A Phase 1 interventional study of Ritlecitinib 50 mg and Ritlecitinib 200 mg in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a phase 1, open label, two-arm study to assess target occupancy and functional inhibition of JAK3 and TEC kinases by Ritlecitinib in healthy adult participants

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all the following criteria apply:

  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination including BP and pulse rate measurement, 12-lead , or clinical and laboratory tests.
  • of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Infection with , or viruses
  • Have evidence of untreated or inadequately treated active or latent Mycobacterium TB infection
  • Known active or history of recurrent bacterial, viral, fungal, mycobacterial or other infections.
  • Have received only one of the 2 required doses of COVID-19 vaccine.
  • Participants have a known present or a history of other than a successfully treated or excised non basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Subjects will be dosed with 50 mg Ritlecitinib on Day 1 and followed up till Day 3

    Drug: Ritlecitinib 50 mg

  • Experimental
    Cohort 2

    Subjects will be dosed with 200 mg Ritlecitinib on Day 1 and followed up till Day 3

    Drug: Ritlecitinib 200 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Target Occupancy for JAK3

    Target occupancy for janus kinase 3 (JAK3) in peripheral blood mononuclear cells (PBMCs) by ritlecitinib was investigated in human blood by chemical probe-based enrichment and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

    Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose

  2. Percent Target Occupancy for BTK

    Target occupancy for Bruton's tyrosine kinase (BTK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

    Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose

  3. Percent Target Occupancy for ITK

    Target occupancy forIL 2 inducible T-cell kinase (ITK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

    Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose

  4. Percent Target Occupancy for TXK

    Target occupancy for tyrosine kinase expressed in T cells (TXK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

    Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose

  5. Percent Target Occupancy for TEC

    Target occupancy for tyrosine kinase expressed carcinoma (TEC) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

    Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose

  6. Percent Target Occupancy for BMX

    Target occupancy for bone marrow tyrosine kinase gene in chromosome X (BMX) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point) \*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

    Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Ritlecitinib

    Cmax is maximum observed plasma concentration. Cmax for ritlecitinib was observed directly from data.

    Time frame: 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ritlecitinib

    Tmax is time for Cmax. Tmax for ritlecitinib was observed directly from data as time of first occurrence.

    Time frame: 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose

  3. Last Quantifiable Plasma Concentration (Clast) of Ritlecitinib

    Clast is last quantifiable plasma concentration. Clast for ritlecitinib was observed directly from data.

    Time frame: 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose

  4. Average Plasma Concentration From Time 0 to 24 Hours (Cav) of Ritlecitinib

    Cav is average plasma concentration from time 0 to 24 hours over the 24 hours period. Cav for ritlecitinib was calculated as area under the plasma concentration-time curve from 0 to 24 hours (AUC24) divided by 24.

    Time frame: 0 (pre-dose), 1, 2, 4, 8, 24 hours post-dose

  5. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Ritlecitinib

    AUClast is area under the plasma concentration-time profile from time 0 to the time of the Clast. AUClast for ritlecitinib was determined using linear/log trapezoidal method.

    Time frame: 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose

  6. Area Under the Curve From Time 0 to 24 Hours (AUC24) of Ritlecitinib

    AUC24 is area under the plasma concentration-time curve from time 0 to 24 hours. AUC24 for ritlecitinib was determined using linear/log trapezoidal method.

    Time frame: 0 (pre-dose), 1, 2, 4, 8, 24 hours post-dose

  7. Number of Participants With All-Causality and Treatment-Related Treatment-Emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)

  8. Number of Participants With Treatment-Emergent Adverse Events by Severity

    An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. Treatment-emergent are events between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs are classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.

    Time frame: From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)

  9. Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

    Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocyte, platelet, neutrophils, eosinophils, monocytes, basophils, lymphocytes, etc), chemistry (glucose, calcium, sodium, potassium, chloride, total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, etc), and urinalysis (glucose, protein, hemoglobin, ketones, nitrite, leukocytes, urine bacteria, etc). Baseline = the pre-dose measurement on Day -1. Laboratory abnormalities meeting pre-defined criteria are reported for this outcome measure. Only those categories in which at least 1 participant had data were reported. ULN=upper limit of normal. LPF=low power field.

    Time frame: From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)

  10. Number of Participants With Pre-defined Criteria for Vital Signs

    Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) supine DBP: less than (\<) 50 mmHg, b) supine DBP: change of \>= 20mmHg increase, c) supine DBP: change of \>= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) supine SBP: \<90 mmHg, b) supine SBP: change of \>=30mmHg increase, c) supine SBP: change of \>=30mmHg decrease; 3) Supine pulse rate, a) \<40 bpm, b) \>120 bpm. mmHg=millimeters of mercury, bpm=beats per minute.

    Time frame: From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)

07

Results

Posted Nov 13, 2023

Participant flow

Participant flow — Overall Study
MilestoneRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Started88
Completed88
Not completed00

Outcome measures

PrimaryPercent Target Occupancy for JAK3

Target occupancy for janus kinase 3 (JAK3) in peripheral blood mononuclear cells (PBMCs) by ritlecitinib was investigated in human blood by chemical probe-based enrichment and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

Time frame:
-1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Reported as:
Median · percentage of occupancy
Percent Target Occupancy for JAK3
percentage of occupancyRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Baseline0.00 (0.0 to 0.0)0.00 (0.0 to 0.0)
1H72.41 (49.2 to 98.0)28.74 (-5.8 to 51.1)
2H12.28 (-30.1 to 39.5)64.14 (54.1 to 75.0)
4H-1.39 (-19.6 to 5.2)62.06 (45.3 to 73.9)
8H-23.34 (-49.1 to 17.7)58.76 (38.9 to 65.2)
24H-24.72 (-58.2 to -10.2)37.08 (30.2 to 53.1)
48H-25.34 (-51.8 to 3.7)33.44 (9.4 to 52.9)
PrimaryPercent Target Occupancy for BTK

Target occupancy for Bruton's tyrosine kinase (BTK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

Time frame:
-1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Reported as:
Median · percentage of occupancy
Percent Target Occupancy for BTK
percentage of occupancyRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Baseline0.00 (0.0 to 0.0)0.00 (0.0 to 0.0)
1H98.45 (95.4 to 99.8)99.57 (98.2 to 99.8)
2H96.83 (92.1 to 99.2)99.37 (98.6 to 99.8)
4H96.43 (90.4 to 99.1)99.35 (99.2 to 99.8)
8H93.52 (85.3 to 97.8)99.21 (97.1 to 99.5)
24H83.21 (76.5 to 86.3)92.13 (87.0 to 95.5)
48H69.86 (63.3 to 76.4)82.66 (75.8 to 88.1)
PrimaryPercent Target Occupancy for ITK

Target occupancy forIL 2 inducible T-cell kinase (ITK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

Time frame:
-1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Reported as:
Median · percentage of occupancy
Percent Target Occupancy for ITK
percentage of occupancyRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Baseline0.00 (0.0 to 0.0)0.00 (0.0 to 0.0)
1H94.40 (86.2 to 100.0)97.03 (73.8 to 98.0)
2H67.77 (42.2 to 88.4)97.06 (94.5 to 98.1)
4H57.54 (23.0 to 73.9)92.27 (86.0 to 97.4)
8H28.76 (-5.5 to 58.0)76.59 (60.0 to 88.9)
24H-16.77 (-42.1 to 30.5)32.33 (12.4 to 43.8)
48H-9.87 (-61.0 to 21.6)20.62 (-16.0 to 44.7)
PrimaryPercent Target Occupancy for TXK

Target occupancy for tyrosine kinase expressed in T cells (TXK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

Time frame:
-1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Reported as:
Median · percentage of occupancy
Percent Target Occupancy for TXK
percentage of occupancyRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Baseline0.00 (0.0 to 0.0)0.00 (0.0 to 0.0)
1H100.00 (88.6 to 100.0)100.00 (37.7 to 100.0)
2H44.97 (27.1 to 66.7)100.00 (100.0 to 100.0)
4H34.01 (-15.8 to 52.1)100.00 (87.9 to 100.0)
8H23.17 (-41.0 to 60.7)82.46 (63.1 to 100.0)
24H-4.09 (-43.4 to 31.4)49.70 (33.2 to 59.7)
48H-38.98 (-83.7 to 17.7)20.34 (1.9 to 58.8)
PrimaryPercent Target Occupancy for TEC

Target occupancy for tyrosine kinase expressed carcinoma (TEC) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

Time frame:
-1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Reported as:
Median · percentage of occupancy
Percent Target Occupancy for TEC
percentage of occupancyRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Baseline0.00 (0.0 to 0.0)0.00 (0.0 to 0.0)
1H96.50 (87.4 to 100.0)100.0 (96.0 to 100.0)
2H94.60 (88.3 to 98.0)99.42 (98.3 to 100.0)
4H94.23 (90.9 to 98.3)98.78 (98.1 to 100.0)
8H93.12 (85.5 to 98.6)99.57 (97.4 to 100.0)
24H90.64 (83.7 to 95.8)96.85 (94.1 to 97.8)
48H82.48 (75.7 to 87.3)92.32 (87.9 to 94.8)
PrimaryPercent Target Occupancy for BMX

Target occupancy for bone marrow tyrosine kinase gene in chromosome X (BMX) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point) \*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.

Time frame:
-1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Reported as:
Median · percentage of occupancy
Percent Target Occupancy for BMX
percentage of occupancyRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Baseline0.00 (0.0 to 0.0)0.00 (0.0 to 0.0)
1H67.51 (-16.4 to 96.0)99.13 (91.9 to 100.0)
2H85.26 (68.5 to 100.0)92.53 (88.7 to 100.0)
4H84.93 (76.0 to 100.0)92.26 (87.7 to 100.0)
8H87.08 (69.9 to 95.3)92.48 (85.0 to 98.7)
24H68.13 (51.5 to 87.9)91.32 (82.1 to 97.9)
48H26.50 (-15.6 to 54.1)62.34 (52.5 to 79.4)
SecondaryMaximum Observed Plasma Concentration (Cmax) of Ritlecitinib

Cmax is maximum observed plasma concentration. Cmax for ritlecitinib was observed directly from data.

Time frame:
0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Ritlecitinib
nanogram/milliliter (ng/mL)RITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Maximum Observed Plasma Concentration (Cmax) of Ritlecitinib297.1 ± 511275 ± 20
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Ritlecitinib

Tmax is time for Cmax. Tmax for ritlecitinib was observed directly from data as time of first occurrence.

Time frame:
0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Reported as:
Median · hour (hr)
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ritlecitinib
hour (hr)RITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ritlecitinib1.00 (1.00 to 2.00)1.00 (1.00 to 2.00)
SecondaryLast Quantifiable Plasma Concentration (Clast) of Ritlecitinib

Clast is last quantifiable plasma concentration. Clast for ritlecitinib was observed directly from data.

Time frame:
0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Reported as:
Geometric mean · ng/mL
Last Quantifiable Plasma Concentration (Clast) of Ritlecitinib
ng/mLRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Last Quantifiable Plasma Concentration (Clast) of Ritlecitinib4.812 ± 874.036 ± 666
SecondaryAverage Plasma Concentration From Time 0 to 24 Hours (Cav) of Ritlecitinib

Cav is average plasma concentration from time 0 to 24 hours over the 24 hours period. Cav for ritlecitinib was calculated as area under the plasma concentration-time curve from 0 to 24 hours (AUC24) divided by 24.

Time frame:
0 (pre-dose), 1, 2, 4, 8, 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Average Plasma Concentration From Time 0 to 24 Hours (Cav) of Ritlecitinib
ng/mLRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Average Plasma Concentration From Time 0 to 24 Hours (Cav) of Ritlecitinib28.42 ± 51144.9 ± 42
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Ritlecitinib

AUClast is area under the plasma concentration-time profile from time 0 to the time of the Clast. AUClast for ritlecitinib was determined using linear/log trapezoidal method.

Time frame:
0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Reported as:
Geometric mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Ritlecitinib
nanogram*hour/milliliter (ng*hr/mL)RITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Ritlecitinib651.4 ± 503382 ± 43
SecondaryArea Under the Curve From Time 0 to 24 Hours (AUC24) of Ritlecitinib

AUC24 is area under the plasma concentration-time curve from time 0 to 24 hours. AUC24 for ritlecitinib was determined using linear/log trapezoidal method.

Time frame:
0 (pre-dose), 1, 2, 4, 8, 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time 0 to 24 Hours (AUC24) of Ritlecitinib
ng*hr/mLRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Area Under the Curve From Time 0 to 24 Hours (AUC24) of Ritlecitinib681.8 ± 513475 ± 42
SecondaryNumber of Participants With All-Causality and Treatment-Related Treatment-Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)
Reported as:
Count of participants · Participants
Number of Participants With All-Causality and Treatment-Related Treatment-Emergent Adverse Events (TEAEs)
ParticipantsRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Number of Participants with all-causality TEAEs32
Number of Participants with all-causality SAEs00
Number of Participants with treatment-related TEAEs00
Number of Participants with treatment-related SAEs00
SecondaryNumber of Participants With Treatment-Emergent Adverse Events by Severity

An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. Treatment-emergent are events between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs are classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.

Time frame:
From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events by Severity
ParticipantsRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Mild (all causalities)32
Moderate (all causalities)00
Severe (all causalities)00
Mild (treatment-related)00
Moderate (treatment-related)00
Severe (treatment-related)00
SecondaryNumber of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocyte, platelet, neutrophils, eosinophils, monocytes, basophils, lymphocytes, etc), chemistry (glucose, calcium, sodium, potassium, chloride, total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, etc), and urinalysis (glucose, protein, hemoglobin, ketones, nitrite, leukocytes, urine bacteria, etc). Baseline = the pre-dose measurement on Day -1. Laboratory abnormalities meeting pre-defined criteria are reported for this outcome measure. Only those categories in which at least 1 participant had data were reported. ULN=upper limit of normal. LPF=low power field.

Time frame:
From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
ParticipantsRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Monocytes/Leukocytes (%) >1.2*ULN02
Urine Nitrite >=111
Urine Bacteria (/LPF) >2010
SecondaryNumber of Participants With Pre-defined Criteria for Vital Signs

Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) supine DBP: less than (\<) 50 mmHg, b) supine DBP: change of \>= 20mmHg increase, c) supine DBP: change of \>= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) supine SBP: \<90 mmHg, b) supine SBP: change of \>=30mmHg increase, c) supine SBP: change of \>=30mmHg decrease; 3) Supine pulse rate, a) \<40 bpm, b) \>120 bpm. mmHg=millimeters of mercury, bpm=beats per minute.

Time frame:
From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)
Reported as:
Count of participants · Participants
Number of Participants With Pre-defined Criteria for Vital Signs
ParticipantsRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Supine DBP <50 mmHg00
Supine DBP change >= 20mmHg increase00
Supine DBP change >= 20mmHg decrease00
Supine SBP <90 mmHg00
Supine SBP change >=30mmHg increase00
Supine SBP change >=30mmHg decrease00
Supine pulse rate <40 bpm00
Supine pulse rate >120 bpm00

Adverse events

Collected over Baseline up to 35 days after the last dose of study treatment on Day 1 (up to 35 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RITLECITINIB 50 MG CAPSULE0/8 (0%)0/8 (0%)3/8 (37.5%)
RITLECITINIB 200 MG CAPSULE0/8 (0%)0/8 (0%)2/8 (25%)
Most frequent other events
Most frequent other events
EventRITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULE
Abdominal distensionGastrointestinal disorders1/80/8
DyspepsiaGastrointestinal disorders1/80/8
Escherichia urinary tract infectionInfections and infestations1/80/8
Gastroenteritis viralInfections and infestations0/81/8
Procedural dizzinessInjury, poisoning and procedural complications0/81/8
Pain in extremityMusculoskeletal and connective tissue disorders1/80/8

Baseline characteristics

Baseline analysis population included all enrolled participants who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(Years)RITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULETotal
Mean43.9 ± 10.9537.9 ± 12.9740.9 ± 12.0
Age, Customized
Age, Customized(Participants)RITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULETotal
<18000
18-44347
45-64549
>=65000
Sex: Female, Male
Sex: Female, Male(Participants)RITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULETotal
Female426
Male4610
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULETotal
Hispanic or Latino101
Not Hispanic or Latino7815
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RITLECITINIB 50 MG CAPSULERITLECITINIB 200 MG CAPSULETotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American325
White448
More than one race101
Unknown or Not Reported000
08

Study locations

1 site
  • Pfizer Clinical Research Unit - New Haven
    New Haven, Connecticut 06511, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jan 2022, 2 months.

Results were first posted in Nov 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Nov 19, 2021
StartActual
Oct 22, 2021
Primary completionActual
Jan 14, 2022
CompletionActual
Jan 14, 2022
Results first posted
Nov 13, 2023
Last update
Nov 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05128058
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 19, 2021
Start date
Oct 22, 2021
Primary completion
Jan 14, 2022
Completion
Jan 14, 2022
Results posted
Nov 13, 2023
Last update
Nov 13, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion